Category Archives: 2019Q4

Hanesbrands debt reduced from 3.3 to 2.9 times EBITDA and share repurchase of $200M planned in early 2020, but shares remain undervalued

Record net cash from operations of $803 million for full year. Guidance for 2020 is $700-800M. Expectation of $200 million in share repurchases early in 2020. Debt repayments greater than $600 million in 2019 and year-end inventory 7% lower. Net debt reduced from 3.3 to 2.9 times adjusted EBITDA. Shares seems undervalued given low multiples, …

Continue reading “Hanesbrands debt reduced from 3.3 to 2.9 times EBITDA and share repurchase of $200M planned in early 2020, but shares remain undervalued”

Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued

Anti-diabetic oral GLP1 drug Rybelsus® (semaglutide) received FDA approval on September 20th and 70%-80% of patients are not coming from other injectables. GLP1 drug segment is growing led by the weekly injectable anti-diabetic drug Ozempic® (semaglutide) approved for CV risk reduction in the US. Revenue in US diabetes segment is flat due to declining revenue …

Continue reading “Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued”